HUTCHMED Receives the NMPA’s Breakthrough Therapy Designation for Fruquintinib + Sintilimab to Treat Advanced Endometrial Cancer
Shots:
- The NMPA has granted BTD to the combination of fruquintinib and sintilimab for the treatment of patients with advanced EMC with pMMR1 tumors that have failed one line of Pt-based therapy
- The patient enrolment has been completed in the open-label study. The 1EPs of the study are IRC assessed ORR & the 2EPs incl. DCR, PFS, OS, as well as PK assessments while regulatory approval application may be submitted to the NMPA in H1’23 if this trial's results are encouraging
- Fruquintinib, a highly selective and potent oral inhibitor of VEGFR -1, -2, and -3. The therapy was approved for marketing in China in Sept 2018 and commercially launched in Nov 2018 under the brand name Elunate for metastatic CRC patients
Ref: Globenewswire | Image: HUTCHMED
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
